Market Applicability								
Market	DC	GA	КҮ	MD	NJ	NY	WA	
Applicable	Х	Х	Х	Х	Х	Х	Х	

Elitek (rasburicase)

Override(s)	Approval Duration			
Prior Authorization	1 course of therapy (once daily for 5			
	days)			

Medications	
Elitek (rasburicase)	

APPROVAL CRITERIA

Requests for Elitek (rasburicase) may be approved if the following criteria are met:

- I. Individual has a diagnosis of hyperuricemia due to malignancy; **AND**
- II. Individual is receiving chemotherapy for leukemia, lymphoma or other hematologic malignancy, or solid tumors with risk factors for tumor lysis syndrome; **AND**
- III. Individual is receiving treatment in a setting appropriate for providing necessary monitoring and supportive care for tumor lysis syndrome.

Requests for Elitek (rasburicase) may not be approved for the following:

- I. Individual has a diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency; OR
- II. Individual has received a course of Elitek therapy in the past; OR
- III. When the above criteria are not met and for all other indications.

Note:

Elitek (rasburicase) has a black box warning regarding the potential to cause severe hypersensitivity (up to and including anaphylaxis), hemolysis, and methemoglobinemia. With regard to hypersensitivity reactions, hemolysis and methemoglobinemia, if any of these reactions occur; Elitek should be immediately and permanently discontinued. In addition, Elitek should not be administered in individuals with a glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <u>http://www.clinicalpharmacology.com</u>. Updated periodically.

CRX-ALL-0510-20

PAGE 1 of 2 02/11/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability								
Market	DC	GA	КҮ	MD	NJ	NY	WA	
Applicable	Х	Х	Х	Х	Х	Х	Х	

- 2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website.
- http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: September 27, 2019.
- DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
 Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.